Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients

References

• Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(3):355–14. Epub 2017/02/17. PubMed PMID: 28026041; PubMed Central PMCID: PMCPMC5396275.
   PubMed Web of Science ®Google Scholar
• Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124. Epub 2017/07/06. PubMed PMID: 28676062; PubMed Central PMCID: PMCPMC5496354.
   PubMedGoogle Scholar
• De Sanctis R, Pane M, Coratti G, et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul Disord. 2018;28(1):24–28. Epub 2017/ 10/10. PubMed PMID: 29174525.
   Web of Science ®Google Scholar
• De Sanctis R, Coratti G, Pasternak A, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26(11):754–759. Epub 2016/10/05. PubMed PMID: 27769560; PubMed Central PMCID: PMCPMC5091285.
   PubMed Web of Science ®Google Scholar
• Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810–817. Epub 2014/07/30. PubMed PMID: 25080519; PubMed Central PMCID: PMCPMC4155049.
   PubMed Web of Science ®Google Scholar
• Lefebvre S, Bürglen L, Frézal J, et al. The role of the SMN gene in proximal spinal muscular atrophy. Hum Mol Genet. 1998;7(10): 1531–1536. PubMed PMID: 9735373.
   PubMed Web of Science ®Google Scholar
• Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157–167. Epub 2014/ 12/16. PubMed PMID: 25346245; PubMed Central PMCID: PMCPMC4293319.
   PubMed Web of Science ®Google Scholar
• Lally C, Jones C, Farwell W, et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the USA. Orphanet J Rare Dis. 2017;12(1):175. Epub 2017/11/28. doi: . PubMed PMID: 29183396; PubMed Central PMCID: PMCPMC5704427.
   PubMedGoogle Scholar
• Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics. PubMed PMID: 14711346 Expert Rev Mol Diagn. 2004;41:15–29.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1723–1732. Epub 2017/11/02. PubMed PMID: 29091570.
   PubMed Web of Science ®Google Scholar
• Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–115. Epub 2017/11/23. PubMed PMID: 29290580.
   PubMed Web of Science ®Google Scholar
• Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197–207. Epub 2017/11/23. PubMed PMID: 29305137.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017;377(18):1713–1722. PubMed PMID: 29091557.
   PubMed Web of Science ®Google Scholar
• Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119(13):3038–3041. Epub 2012/01/23. PubMed PMID: 22271447; PubMed Central PMCID: PMCPMC3321866.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Al-Zaidy S, Shell R, et al. AVXS-101 Phase 1 gene replacement therapy clinical trial in SMA type 1: continued event-free survival and achievement of developmental milestones. 22nd Annual SMA Researcher Meeting; June 14-16, 2018; Dallas, TX2018.
   Google Scholar
• Shell R, Kotha K, Al-Zaidy S AVXS-101 Phase 1 gene replacement therapy clinical trial in SMA type 1: continued independence from nutritional and ventilatory support in patients dosed early in disease progression after 24 months post-dosing. American Academy of Neurology Annual Meeting; Los Angeles, CA2018.
   Google Scholar
• Avexis. The first SMA Gene Therapy in Human Trials 2018 [cited August 8, 2018]. Available from: https://www.avexis.com/research-and-development.
   Google Scholar
• Zuluaga-Sanchez S, Knight C, Thompson R, et al. Adequately reflecting the clinical benefits in rare disease economic modelling using SMA type 1 (Infantile Onset) as a case study. ISPOR 20th Annual European Congress; 4-8 November 2017; Glasgow, Scotland.
   Google Scholar
• Landfeldt E, Alfredsson L, Straub V, et al. Economic evaluation in duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. PubMed PMID: 27798808; PubMed Central PMCID: PMCPMC5253157 Pharmacoeconomics. 2017;352:249–258.
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Gallop K, Thompson R, et al. Estimation of the health-related quality of life benefits of treatment for Spinal Muscular Atrophy (SMA). ISPOR 20TH Annual European Congress 4–8 November 2017; Glasgow, Scotland.
   Google Scholar
• Thompson R, Vaidya S, Teynor M The utility of different approaches to developing health utilities data in childhood rare diseases – A case study in spinal muscular atrophy (SMA). ISPOR 20TH Annual European Congress 4–8 November 2017; Glasgow, Scotland.
   Google Scholar
• Othus M, Bansal A, Koepl L, et al. Accounting for Cured Patients in Cost-Effectiveness Analysis. Value Health. 2017;20(4):705–709. Epub 2016/ 06/09. PubMed PMID: 28408015.
   PubMed Web of Science ®Google Scholar
• Crowther MJ, Lambert PC. Parametric multistate survival models: flexible modelling allowing transition-specific distributions with application to estimating clinically useful measures of effect differences. Stat Med. 2017;36(29):4719–4742. Epub 2017/ 09/05. PubMed PMID: 28872690.
   PubMed Web of Science ®Google Scholar
• Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1): 67–72. PubMed PMID: 9077498.
   PubMed Web of Science ®Google Scholar
• Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883–891. Epub 2017/12/08. PubMed PMID: 29149772; PubMed Central PMCID: PMCPMC5776712.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. PubMed PMID: 24338265 Pharmacoeconomics. 2014;322:101–108.
   PubMed Web of Science ®Google Scholar
• Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol Epub 2011/ 10/10. 2011;11:139. PubMed PMID: 21985358; PubMed Central PMCID: PMCPMC3198983.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials Epub 2007/06/07. PubMed PMID: 17555582; PubMed Central PMCID: PMCPMC1920534. 2007;8:16. .
   PubMed Web of Science ®Google Scholar
• Jackson C. flexsurv: A Platform for Parametric Survival Modeling in R. J Statist Software. 2016;70(8):1–33.
   Web of Science ®Google Scholar
• Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children‘s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Pediatr Phys Ther. 2011;23(4):322–326. PubMed PMID: 22090068.
   PubMed Web of Science ®Google Scholar
• Shieh PB, Gu T, Chen E, et al. Treatment patterns and cost of care among patients with Spinal Muscular Atrophy. Cure SMA Annual Meeting; June 29-July 1, 2017; Orlando, FL2017.
   Google Scholar
• Biogen. A guide to Spinraza reimbursement: important information to help navigate the access and reimbursement process. 2016. Available from: https://www.spinraza-hcp.com/content/dam/commercial/specialty/spinraza/hcp/en_us/pdf/SPZ-US-0134_Reimbursement-Guide.pdf.
   Google Scholar
• Garrison LP, Jackson T, Paul D, et al. Value-Based Pricing for Emerging Gene Therapies: the Economic Case for a Higher Cost-Effectiveness Threshold. J Manag Care Spec Pharm. 2019:1-7. doi: 10.18553/jmcp.2019.18378.
   Web of Science ®Google Scholar
• Postma MJ, Parouty M, Westra TA. Accumulating evidence for the case of differential discounting. PubMed PMID: 23272787 Expert Rev Clin Pharmacol. 2013;61:1–3.
   PubMed Web of Science ®Google Scholar
• Dreitlin B, Towse A, Watkins JB, et al. Developing and paying for gene therapies - can we resolve the conflicts?. Value Outcomes Spotlight. 2018 Jan/Feb;31–34.
   Google Scholar
• Hampson G, Towse A, Pearson SD, et al. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15–28.
   PubMed Web of Science ®Google Scholar
• Ralston S, Floyd D, Ratcliffe M. Differential discounting: capturing the value of living longer and better. Value Health. 2013;16(7):A467.
   Web of Science ®Google Scholar
• Lopez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, et al. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1):141. Epub 2017/08/20. PubMed PMID: 28821278; PubMed Central PMCID: PMCPMC5563035.
   PubMedGoogle Scholar
• New SPINRAZA® (nusinersen) data presented at annual congress of the world muscle society demonstrate benefits in treating presymptomatic infants with spinal muscular atrophy. Available from: http://investors.biogen.com/news-releases/news-release-details/new-spinrazar-nusinersen-data-presented-annual-congress-world.
   Google Scholar
• FDA. CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER:209531Orig1s000 MEDICAL REVIEW(S). [cited 2019 Mar 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/209531orig1s000medr.pdf
   Google Scholar
• Darras B, Royden Jones H, Ryan M, et al. Neuromuscular Disorders of Infancy, Childhood and Adolescence: A clinician‘s approach. 2nd ed. London, UK: Elsevier; 2015.
   Google Scholar
• Fang P, Li L, Zeng J, et al. Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls. BMC Musculoskelet Disord. 2015;16:11. Epub 2015/02/07. PubMed PMID: 25888055; PubMed Central PMCID: PMCPMC4328246.
   Web of Science ®Google Scholar
• Kuester MK, Jackson EA, Runyan BM, et al. The Effect of a Pediatric Rare Disease on Subscriber Retention Rates for Commercial Health Insurers in the USA. J Manag Care Spec Pharm. 2019;25(2):186–195. Epub 2018/ 09/27. PubMed PMID: 30256693.
   Web of Science ®Google Scholar
• Usdin S. Biocentury. Focusing on Cures. Available from: https://www.biocentury.com/printpdf/300659.
   Google Scholar
• Gregoretti C, Ottonello G, Chiarini Testa MB, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131(5):e1509–14. Epub 2013/04/24. doi: . PubMed PMID: 23610208.
   PubMed Web of Science ®Google Scholar
• Khan KA, Petrou S, Rivero-Arias O, et al. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics. 2014;32(7):693–706. Epub 2014/04/10. PubMed PMID: 24715604.
   PubMed Web of Science ®Google Scholar
• Graham RJ, Athiraman U, Laubach AE, et al. Anesthesia and perioperative medical management of children with spinal muscular atrophy. Paediatr Anaesth. 2009;19(11):1054–1063. Epub 2009/06/25. PubMed PMID: 19558636.
   Web of Science ®Google Scholar
• Cardenas J, Menier M, Heitzer MD, et al. High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): retrospective Analysis of the Kids‘ Inpatient Database (KID). Pharmacoecon Open. 2018. Epub 2018/ 09/06. DOI: 10.1007/s41669-018-0093-0. PubMed PMID: 30182345.
   Web of Science ®Google Scholar